Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences

ANN ARBOR, MI / ACCESSWIRE / February 8, 2024 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the continuation of its veterinary education mission through recent and upcoming presentations at the Veterinary Meeting and Expo (“VMX”) and Western Veterinary Conference (“WVC”) meetings.

“At Zomedica, we feel strongly about giving back to the veterinary community. These meetings are amongst the most prominent and well-attended annual educational symposiums in veterinary healthcare, with combined attendance of over 47,000 veterinary professionals,” commented Nicole Westfall, Zomedica’s Senior Vice-President of Marketing. “They not only support the continuing education of veterinary healthcare professionals but also provide high visibility to the many benefits of Zomedica’s innovative diagnostic and therapeutic products. In 2023, over 150 continuing education hours were provided to veterinary professionals by Zomedica. We are off to a great start in 2024, with over 400 attendees at educational presentations sponsored by Zomedica at VMX.”

Topics included “Helping Senior Dogs Move and Thrive” by Leilani Alvarez, DVM, DACVSMR, “On Guard: How to Stay Vigilant in Immediate Post Op Management” by Courtney Campbell, DVM, DACVS and “Digital Derm: How to Implement Cytology in Your Busy Practice” by Ashley Bourgeois DVM, DACVD.

“We are truly honored to be able to work closely with such prominent and influential veterinary leaders as Drs. Alvarez, Campbell and Bourgeois,” said Zomedica’s Vice-President of Clinical & Veterinary Affairs, Adrian Lock. “To have their support and see the difference we can make together through education is incredibly rewarding.”

Highlighting recent releases of new assays, including cPL, Cobalamin and Folate for the TRUFORMA Bulk Acoustic Wave sensor platform for canine non-infectious gastrointestinal disease and the first point-of-care assay for eACTH for diagnosis of equine Cushing’s disease, Zomedica had a strong presence at VMX, with hundreds of visitors to the booth.

“Momentum has been building with all of our product lines, and we are excited to continue that strong trend in 2024,” commented Senior Vice President of Sales, Kevin Klass.

Zomedica will be attending and exhibiting at the Western Veterinary Annual Conference from February 18 – 21, 2024, in Las Vegas, Nevada at Booth #2544, which will feature additional presentations sponsored by Zomedica, from luminaries in the field of veterinary medicine:

• Beau Whitaker, DVM, CERP – “Shockwave Therapy for Treatment of EIPH in Barrel Horses”
• Kara M. Burns, MS, Med, LVT, VTS (Nutrition) – “Managing Pain and Inflammation in Osteoarthritis”
• Courtney Campbell, DVM, DACVS – “Beyond Surgery: Convention and Untapped Remedies for Maximizing Postoperative Success”
• Gary Oswald, DVM, DACVIM – “Have the “Guts” to run these tests? The Importance of Gastrointestinal Blood Panels”
• Fred Wininger, VMD, MS, DACVIM (Neurology) & Chris Pachel, DVM, DACVB – “Brain or Mind? Where Veterinary Behavior and Neurology Collide”
• Leilani Alvarez, DVM, DACVSMR – “Helping Senior Dogs Move and Thrive”
• Ashley Bourgeois, DVM, DACVD – Digital Derm; “How to Implement Cytology in Your Busy Practice”

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica’s mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com
• LinkedIn: https://www.linkedin.com/company/zomedica
• Facebook: https://m.facebook.com/zomedica
• Twitter: https://twitter.com/zomedica
• Instagram: https://www.instagram.com/zomedica_inc

Cautionary Statement Regarding Forward-Looking Statements – Safe Harbor

Except for statements of historical fact, this news release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555

SOURCE: Zomedica Corp.

View the original press release on accesswire.com